A director at Fulgent Genetics Inc bought 100,000 shares at 15.965USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021 TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its first quarter 2021 financial results after the market closes on Thursday May 6, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthui...
Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus Agreement leverages Fulgent’s Next Generation Sequencing (“NGS”) capabilities for genomic sequencing to aid in ongoing research of SARS-CoV-2, the virus that causes COVID-19 TEMPLE CITY, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable platform, today announced that the U.S. Centers for Disease Control and Prevention (“CDC”) has awarded the Company a contra...
Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference TEMPLE CITY, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021...
Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 Results: Record Revenue of $295.0 million, growing more than 3,400% year-over-yearRecord Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019Gross Margin improved over 8 percentage points sequentially and approximately 26 percentage points year-over-year; cost per test improved approximately 36% sequentiallyNon-COVID Revenue grew 43% year-over-yearRecord GAAP income of $166.3 million, or $6.16 per shareRecord Non-GAAP income of ...
Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021 TEMPLE CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday March 4, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief C...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference TEMPLE CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in a presentation at the H.C. Wainwright BIOCONNECT 2021 Conference taking place January 11 to 14, 2021. A webcast of the presentat...
Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year Following a competitive process, Fulgent was selected to extend its support of the NYC DOE public school testing managed by the NYC Test and Trace Corps with on-site staffing and RT-PCR tests through the remainder of the 2021 school year TEMPLE CITY, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Compan...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healthcare Conference TEMPLE CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis virtually participated in a pre-recorded fireside chat that will be published as part of the Piper Sandler 32nd Annua...
Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million TEMPLE CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has updated its revenue guidance for the full year 2020 due to accelerating demand for its COVID-19 testing solutions. The company now expects to generate at least $300 million in revenue for the full year 2020, an increase of 28% compared to previous gu...
Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representatives of...
Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million Third Quarter 2020 Results: Record Revenue of $101.7 million, growing more than 880% year-over-yearRecord Billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-yearGross Margin improved approximately 19 percentage points sequentially and approximately 12 percentage points year-over-year; cost per test improved approximately 42% sequentiallyNon-COVID Revenue grew 57% sequentiallyBolsters reimbursement capability; revenue from reimb...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.